Dr. Carrolee Barlow, M.D., Ph.D., Joins Supernus’ Board of Directors
June 27 2018 - 4:30PM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty
pharmaceutical company focused on developing and commercializing
products for the treatment of central nervous system (CNS)
diseases, today announced that Dr. Carrolee Barlow, M.D., Ph.D.,
has joined Supernus’ Board of Directors effective immediately. Dr.
Barlow is an expert in neuroscience and neurodegeneration, and is
currently the Chief Executive Officer of the Parkinson’s Institute
and Clinical Center, Sunnyvale, California.
“Dr. Barlow’s deep expertise in neurology, as well as her
strategic, operational and academic experience, will add
significant value to our Board and to the Company,” said Jack
Khattar, President and CEO of Supernus Pharmaceuticals. “We look
forward to the contributions and insights Dr. Barlow will offer the
Company as we continue to grow our business."
Dr. Barlow’s previous work has spanned clinical care, laboratory
and clinical research, academia, and industry. She is the former
Chief Scientific Officer and Chief Medical Officer of BrainCells,
Inc., a biotechnology company focused on the discovery and
development of small molecules that stimulate adult hippocampal
neurogenesis for the treatment of neurological and psychiatric
disease. Prior to BrainCells, she served as the Director of
Molecular Neuroscience and Therapeutic Area Head for Stroke and
Neurodegeneration at Merck Research Laboratories where she was
responsible for neuroscience biology, global exploratory,
licensing, and development efforts. Dr. Barlow has held a faculty
position in the Laboratory of Genetics at the Salk Institute for
Biological Studies in La Jolla, California. She also serves as an
advisory board member for several biotechnology companies and
disease foundations advancing therapies for rare diseases and
disorders of the central nervous system.
Dr. Barlow received her Bachelor of Arts in English from The
University of Utah and Doctor of Medicine from The University of
Utah School of Medicine. In addition, she received her Doctor of
Philosophy in molecular and developmental biology from The
Karolinska Medical Nobel Institute in Stockholm, Sweden.
"Supernus has built a successful and growing CNS business and is
working on exciting pipeline opportunities," said Dr. Barlow. "I
look forward to working closely with Supernus' Board and management
team to progress and build on its innovative pipeline."
About Supernus Pharmaceuticals, Inc.Supernus
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on developing and commercializing products for the treatment of
central nervous system diseases. The Company currently markets
Trokendi XR® (extended-release topiramate) for the prophylaxis of
migraine and the treatment of epilepsy, and Oxtellar XR®
(extended-release oxcarbazepine) for the treatment of epilepsy. The
Company is also developing several product candidates to address
large market opportunities in psychiatry, including SPN-810 for the
treatment of Impulsive Aggression in ADHD patients and SPN-812 for
the treatment of ADHD.
Forward-Looking Statements:This press release
includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
do not convey historical information, but relate to predicted or
potential future events that are based upon management's current
expectations. These statements are subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements. In addition to
the factors mentioned in this press release, such risks and
uncertainties include, but are not limited to, the Company’s
ability to sustain and increase its profitability; the Company’s
ability to raise sufficient capital to fully implement its
corporate strategy; the implementation of the Company’s corporate
strategy; the Company’s future financial performance and projected
expenditures; the Company’s ability to increase the number of
prescriptions written for each of its products; the Company’s
ability to increase its net revenue; the Company’s ability to enter
into future collaborations with pharmaceutical companies and
academic institutions or to obtain funding from government
agencies; the Company’s product research and development
activities, including the timing and progress of the Company’s
clinical trials, and projected expenditures; the Company’s ability
to receive, and the timing of any receipt of, regulatory approvals
to develop and commercialize the Company’s product candidates; the
Company’s ability to protect its intellectual property and operate
its business without infringing upon the intellectual property
rights of others; the Company’s expectations regarding federal,
state and foreign regulatory requirements; the therapeutic
benefits, effectiveness and safety of the Company’s product
candidates; the accuracy of the Company’s estimates of the size and
characteristics of the markets that may be addressed by its product
candidates; the Company’s ability to increase its manufacturing
capabilities for its products and product candidates; the Company’s
projected markets and growth in markets; the Company’s product
formulations and patient needs and potential funding sources; the
Company’s staffing needs; and other risk factors set forth from
time to time in the Company’s filings with the Securities and
Exchange Commission made pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934, as amended. The Company undertakes
no obligation to update the information in this press release to
reflect events or circumstances after the date hereof or to reflect
the occurrence of anticipated or unanticipated events.
CONTACTS:
Jack A. Khattar, President and CEOGregory S. Patrick, Vice
President and CFOSupernus Pharmaceuticals, Inc.Tel: (301)
838-2591
or
INVESTOR CONTACT:Peter VozzoWestwicke PartnersOffice: (443)
213-0505Mobile: (443) 377-4767Email: peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Apr 2023 to Apr 2024